Hepcidin-DMT1 interaction and GPRC5D-targeting bispecific antibody for MM

About this episode

This episode features an interview with Drs. Marion Falabrègue and Ajai Chari discussing their research on hepcidin-DMT1 interaction and a bispecific antibody for multiple myeloma.

In this week's episode, Blood editor Dr. Laura Michaelis interviews authors Drs. Marion Falabrègue and Ajai Chari on their papers published in volume 146 issue 24 of Blood . The work of Dr. Falabrègue and colleagues in " Intestinal hepcidin overexpression promotes iron deficiency anemia and counteracts iron overload via DMT1 downregulation " indicates that iron absorption from the apical surface of enterocytes can be modulated through manipulation of the hepcidin-DMT1 interaction, opening new avenues for research and therapeutic manipulation. " Talquetamab plus daratumumab in multiple myeloma " features a phase 1b/2 trial of 65 heavily pretreated patients with MM, where Chari et al combined daratumumab and talquetamab, a GPRC5D-targeting bispecific antibody, reporting depletion of CD38-expressing regulatory T cells following daratumumab and impressive efficacy, with an 80% overall (57% complete) response rate and median progression-free survival of 23.3 months. This regimen is now being evaluated in a phase 3 trial.

People in this episode

Host: Dr. Laura Michaelis

Guests: Dr. Marion Falabrègue, Dr. Ajai Chari

Topics covered

• hepcidin
• DMT1
• multiple myeloma
• bispecific antibody
• iron deficiency anemia
• therapeutic manipulation

Keywords

• hepcidin
• DMT1
• multiple myeloma
• bispecific antibody
• iron absorption
• therapeutic manipulation
• CD38-expressing regulatory T cells
• clinical trial

Mentioned in this episode

Organizations: Blood

Books & works: Intestinal hepcidin overexpression promotes iron deficiency anemia and counteracts iron overload via DMT1 downregulation, Talquetamab plus daratumumab in multiple myeloma

More episodes of Blood Podcast

• Future Directions in Relapsed and Refractory Large B-cell Lymphoma · June 11, 2026 · 25 min
• Review Series on Clonal Tracking in Hematopoiesis · June 4, 2026 · 30 min
• New Approaches: Marstacimab Therapy and HLH Biomarkers · May 28, 2026 · 18 min
• Review Series on Hemophagocytic Lymphohistiocytosis (HLH) · May 21, 2026 · 16 min
• IBD augmentation of CHIP and Platelet mTOR's impact on Cerebral Malaria · May 14, 2026 · 21 min
• Long-term efficacy and safety of betibeglogene autotemcel for β-thalassemia · May 7, 2026 · 13 min